- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05201066
이전에 Novartis가 후원한 Sabatolimab(MBG453) 연구를 완료했으며 연구자가 Sabatolimab을 사용한 지속적인 치료가 도움이 된다고 판단한 환자에 대한 롤오버 연구.
이전에 Novartis가 후원한 Sabatolimab(MBG453) 연구를 완료했고 연구자가 Sabatolimab을 사용한 지속적인 치료가 도움이 된다고 판단한 환자를 위한 공개 라벨, 다기관, 롤오버 연구.
This study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment. The study population consists of participants who tolerate study treatment of the parent studies. Collecting safety information from long-term exposure might offer the unique opportunity to detect rare Adverse Events.
연구 개요
상태
상세 설명
This is a multicenter, open label, roll-over study to collect and assess safety of sabatolimab in participants who are treated in current Novartis-sponsored parent studies and who are benefiting from continued study treatment including sabatolimab as judged by the investigator.
There is no conventional screening period in this study as participants are expected to transition directly from treatment on the parent protocol to treatment on this roll-over protocol. Participants who are candidates for the roll-over protocol will be evaluated by the investigator in the parent protocol for eligibility for the roll-over protocol. If eligible, the parent protocol end of treatment visit will be performed and the informed consent for the roll-over protocol will be signed. Participants then continue treatment on this protocol with the next planned dose of sabatolimab as monotherapy or with other combination agent(s).
The treatment with sabatolimab and combination agent(s), as applicable, is continued according to the schedule in the parent study. Adverse events (AEs) will be collected continuously throughout the study and participants will be questioned about adverse events at each visit.
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
-
Alexandroupoli, 그리스, 681 00
- Novartis Investigative Site
-
Pátrai, 그리스, 265 04
- Novartis Investigative Site
-
-
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, 독일, 79106
- Novartis Investigative Site
-
-
-
-
-
Kuala Lumpur, 말레이시아, 59100
- Novartis Investigative Site
-
-
-
-
Oregon
-
Portland, Oregon, 미국, 97239
- Oregon Health Sciences University
-
-
Utah
-
Salt Lake City, Utah, 미국, 84112-0550
- Huntsman Cancer Institute Univ of Utah
-
-
-
-
Santa Catarina
-
Florianópolis, Santa Catarina, 브라질, 88020-210
- Novartis Investigative Site
-
-
-
-
-
Zurich, 스위스, 8091
- Novartis Investigative Site
-
-
-
-
-
Barcelona, 스페인, 08036
- Novartis Investigative Site
-
Madrid, 스페인, 28009
- Novartis Investigative Site
-
-
Barcelona
-
Badalona, Barcelona, 스페인, 08916
- Novartis Investigative Site
-
-
-
-
BS
-
Brescia, BS, 이탈리아, 25123
- Novartis Investigative Site
-
-
FI
-
Florence, FI, 이탈리아, 50134
- Novartis Investigative Site
-
-
GE
-
Genova, GE, 이탈리아, 16132
- Novartis Investigative Site
-
-
MI
-
Milan, MI, 이탈리아, 20162
- Novartis Investigative Site
-
-
RM
-
Roma, RM, 이탈리아, 00133
- Novartis Investigative Site
-
-
-
-
-
Fukushima, 일본, 9601295
- Novartis Investigative Site
-
-
-
-
-
Tianjin, 중국, 300020
- Novartis Investigative Site
-
-
Jilin
-
Changchun, Jilin, 중국, 130021
- Novartis Investigative Site
-
-
-
-
-
Prague, 체코, 128 08
- Novartis Investigative Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, 캐나다, V5Z 1M9
- Novartis Investigative Site
-
-
-
-
-
Izmir, 터키 (Türkiye), 35100
- Novartis Investigative Site
-
-
-
-
-
Toulouse, 프랑스, 31059
- Novartis Investigative Site
-
-
-
-
Victoria
-
Clayton, Victoria, 호주, 3168
- Novartis Investigative Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Participant is currently enrolled in a Novartis-sponsored study with sabatolimab, is being treated with sabatolimab, and has fulfilled all requirements in the parent study.
- Participant is currently benefiting from the treatment with sabatolimab as determined by guidelines of the parent protocol and investigator's judgment.
- Participant has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.
- Willingness and ability to comply with scheduled visits, treatment plan and any other study procedures.
- Written informed consent obtained prior to enrolling in the roll-over study.
Exclusion Criteria:
- Participants in cohorts or treatment groups not receiving sabatolimab in the parent protocol.
- Participant has been permanently discontinued from sabatolimab treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason.
- Participant currently has unresolved toxicities for which sabatolimab dosing has been interrupted in the parent study (participants meeting all other eligibility criteria may be enrolled once toxicities have resolved to allow sabatolimab dosing to resume).
- Pregnant or nursing (lactating) women. Where pregnancy is defined as the state of a female after conception confirmed by a positive serum hCG laboratory test and until the termination of gestation.
- Participant not willing to comply with the contraception requirements outlined in the exclusion criteria of the parent protocol.
- Local access to commercially available sabatolimab for parent protocol indications.
Other protocol-defined Inclusion/Exclusion may apply.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: sabatolimab + azacitidine
Patients will take sabatolimab 800 mg i.v and azacitidine 75 mg/m2/d d1-7 s.c. or i.v./q4w or sabatolimab 400 mg i.v/q2w and azacitidine 75 mg/m2/d d1-7 s.c. or i.v./q4w. |
Solution for intravenous infusion
다른 이름들:
Solution for subcutaneous injection or intravenous infusion |
|
실험적: sabatolimab + decitabine
Patients will take Sabatolimab 400 mg i.v/q2w and decitabine 20 mg/m2/d d1-5 i.v. |
Solution for intravenous infusion
다른 이름들:
Solution for intravenous infusion |
|
실험적: sabatolimab + venetoclax + azacitidine
Patients will take sabatolimab 200 mg i.v./q2w and venetoclax 400 mg p.o. d1-14/q4wk and azacitidine 75 mg/m2/d d1-7/q4w. |
Solution for intravenous infusion
다른 이름들:
Solution for subcutaneous injection or intravenous infusion Tablet for oral administration |
|
실험적: sabatolimab + spartalizumab + decitabine
Patients will take sabatolimab 400 mg i.v./q2w and decitabine 20 mg/m2/d d1-5 i.v. and spartalizumab 100 mg i.v/q2w. |
Solution for intravenous infusion
다른 이름들:
Solution for intravenous infusion Solution for intravenous infusion
다른 이름들:
|
|
실험적: sabatolimab + HMA
Patients will take sabatolimab 800 mg and azacitidine 75 mg/m2/d d1-7 or decitabine 20 mg/m2/d d1-5/ all q4w HMA means hypomethylating agents. Hypomethylating agents are azacitidine and decitabine. |
Solution for intravenous infusion
다른 이름들:
Tablet for oral administration. HMA = azactidine or decitabine INQOVI = decitabine (oral) |
|
실험적: sabatolimab
Patients will take sabatolimab 800 mg i.v q4w. |
Solution for intravenous infusion
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
기간: 5 years
|
An AE is any untoward medical occurrence (e.g. any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. An AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product. An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing)] undesirable sign(s), symptom(s), or medical conditions(s) which meets any one of the following criteria: fatal, life-threatening, results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, may have caused a congenital anomaly/birth defect, requires intervention to prevent permanent impairment or damage. |
5 years
|
|
Severity of AEs and SAEs
기간: 5 years
|
Severity of AEs and SAEs will be measured according to the CTCAE v5.0 |
5 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Duration of exposure to sabatolimab
기간: 5 years
|
The length of time patients will be exposed to sabatolimab and will be reported by treatment groups. |
5 years
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Novartis Pharmaceuticals, Novartis Pharmaceuticals
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 병리학적 과정
- 신생물
- 만성 질환
- 질병 속성
- 조직학적 유형에 따른 신생물
- 혈액 질환
- 백혈병, 골수성
- 골수이형성-골수증식성 질환
- 골수 질환
- 백혈병
- 병리학적 상태, 징후 및 증상
- 헴 및 림프병
- 백혈병, 골수단구구성, 만성
- 골수이형성 증후군
- 유기 화학 물질
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- 핵산, 뉴클레오티드 및 뉴 클레오 시드
- 시티 딘
- 피리 미딘 뉴 클레오 시드
- 피리 미딘
- 아자 화합물
- 뉴 클레오 시드
- 리보 뉴 클레오 시드
- 데시타빈
- 아자시티딘
- Venetoclax
- Decitabine 및 Cedazuridine 약물 조합
- 스파르타 리즈무 맙
- 사바 톨리 맙
기타 연구 ID 번호
- CMBG453B12206B
- 2021-004422-30 (EudraCT 번호)
- 2024-515281-14-00 (레지스트리 식별자: EU CTIS)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .